Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Clinical CRO Merger: China's dMed Joins Forces with US-Based Clinipace

publication date: Apr 28, 2021

dMed Global, a Shanghai clinical CRO, merged with Clinipace, a North Carolina clinical CRO, to offer cross-border clinical contract research services. In 2016, dMed was founded by Dr. Lingshi Tan, who had been the first General Manager of Pfizer's China R&D Center. In 2019, dMed acquired US-based Target Health, a high-tech CRO with expertise in digital capabilities and regulatory affairs. dMed employs nearly 700 professional staff in more than 31 China cities and three US offices. Both CROs offer services to biotech, pharma and medical device companies. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital